These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 6679010)
1. Venture capital or vulture capital? Knight CJ Life Support Syst; 1983; 1(2):137-40. PubMed ID: 6679010 [No Abstract] [Full Text] [Related]
2. Venture capitalism: a new fashion or new opportunity for European biomedical market development. Knight C Life Support Syst; 1983; 1(3):217-8. PubMed ID: 6679016 [No Abstract] [Full Text] [Related]
3. Mind the (biomedical funding) gap. Klausner A Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055 [No Abstract] [Full Text] [Related]
4. Raising health care capital through the public equity markets. Shields GB; McKann GC Top Health Care Financ; 1986; 12(3):37-53. PubMed ID: 3961804 [No Abstract] [Full Text] [Related]
5. The role of equity financing in today's health care environment. Sykes CS Top Health Care Financ; 1986; 12(3):1-3. PubMed ID: 3961802 [No Abstract] [Full Text] [Related]
6. The stampede to convertibles. Jacobs T Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195 [No Abstract] [Full Text] [Related]
7. Venture capital firms seek good investments. Yanish DL Mod Healthc; 1981 Jun; 11(6):104. PubMed ID: 10251557 [No Abstract] [Full Text] [Related]
8. The WACC method of estimating the discount rate. Clement JP; Suver JD Healthc Financ Manage; 1984 Sep; 38(9):87-8. PubMed ID: 10315602 [No Abstract] [Full Text] [Related]
9. Opportunities for financing new service ventures. Galtney WF Trustee; 1985 Feb; 38(2):40-1. PubMed ID: 10270509 [No Abstract] [Full Text] [Related]
10. Healthcare entices venture capital firms. Colip T; Clinton J Mod Healthc; 1983 Oct; 13(10):74, 76. PubMed ID: 10263455 [No Abstract] [Full Text] [Related]
11. Implications of the method of capital cost payment on the weighted average cost of capital. Boles KE Health Serv Res; 1986 Jun; 21(2 Pt 1):189-212. PubMed ID: 3525468 [TBL] [Abstract][Full Text] [Related]
13. The rise of European venture capital for biotechnology. Howell M; Trull M; Dibner MD Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356 [No Abstract] [Full Text] [Related]
14. Financing bonanza set to continue. Davidson S Nat Biotechnol; 2000 Sep; 18(9):922-3. PubMed ID: 10973203 [No Abstract] [Full Text] [Related]
16. Biotechnology financing dilemmas and the role of special purpose entities. Schiff L; Murray F Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945 [No Abstract] [Full Text] [Related]
17. Why the insurance alternative for access to capital markets is so popular with hospitals. Budnick NP Hosp Cap Finance; 1985; 2(2):2-4. PubMed ID: 10271478 [No Abstract] [Full Text] [Related]
19. Financial services groups sell first taxable pooled financing for hospitals. Graham J Mod Healthc; 1986 Oct; 16(22):114. PubMed ID: 10279068 [No Abstract] [Full Text] [Related]
20. Only the best-laid plans bring capital success. Guncheon KF Hospitals; 1982 Apr; 56(8):72-4. PubMed ID: 7037602 [No Abstract] [Full Text] [Related] [Next] [New Search]